Earnings Feed
Start Free
Home/Filings/4/0001144204-14-003346
4//SEC Filing

CorMedix Inc. 4

Accession 0001144204-14-003346

$CRMDCIK 0001410098operating
View on SEC.govCompany Profile

Filed

Jan 21, 7:00 PM ET

Accepted

Jan 22, 4:09 PM ET

Size

25.7 KB

Accession

0001144204-14-003346

Insider Transaction Report

Form 4
Period: 2014-01-17
CorMedix Inc.CRMD
Gelbfish Gary A.
Director
Transactions
  • Exercise of In-Money

    Common Stock, $0.001 par value per share

    2014-01-17$0.40/sh+250,000$100,000→ 724,382 total
  • Exercise of In-Money

    Warrant (right to purhcase Common Stock)

    2014-01-17−250,000→ 0 total
    Exercise: $0.40From: 2012-09-20Exp: 2017-09-20→ Common Stock, $0.001 par value per share (250,000 underlying)
  • Tax Payment

    Common Stock, $0.001 par value per share

    2014-01-17$2.74/sh−36,455$100,000→ 687,927 total
Holdings

  • Stock Option (right to buy)

    Exercise: $0.90Exp: 2023-03-20→ Common Stock, $0.001 par value per share (50,000 underlying)
    50,000

  • Stock Option (right to buy)

    Exercise: $0.68Exp: 2022-12-05→ Common Stock, $0.001 par value per share (70,000 underlying)
    70,000

  • Stock Option (right to buy)

    Exercise: $2.10Exp: 2021-01-14→ Common Stock, $0.001 par value per share (30,000 underlying)
    30,000

  • Stock Option (right to buy)

    Exercise: $0.29Exp: 2022-01-06→ Common Stock, $0.001 par value per share (30,000 underlying)
    30,000

  • 8% Noteholder Warrants

    Exercise: $3.44Exp: 2016-10-29→ Common Stock, $0.001 par value per share (67,200 underlying)
    67,200

  • Common Stock, $0.001 par value per share

    (indirect: By Foundation)
    78,072

  • Stock Option (right to buy)

    Exercise: $2.02Exp: 2024-01-09→ Common Stock, $0.001 par value per share (30,000 underlying)
    30,000

  • Stock Option (right to buy)

    Exercise: $3.13Exp: 2020-03-30→ Common Stock, $0.001 par value per share (20,000 underlying)
    20,000

  • Stock Option (right to buy)

    Exercise: $2.02Exp: 2024-01-09→ Common Stock, $0.01 par value per share (200,000 underlying)
    200,000

  • Series C-3 Non-Voting Convertible Preferred Stock

    Exercise: $1.00→ Common Stock, $0.01 par value per share (500,000 underlying)
    50,000

  • Warrant (right to purchase Comm Stock)

    Exercise: $1.25From: 2015-01-08Exp: 2020-01-08→ Common Stock, $0.001 par value per share (250,000 underlying)
    250,000

  • 8% Noteholder Warrants

    (indirect: By Foundation)
    Exercise: $3.44Exp: 2016-10-29→ Common Stock, $0.001 par value per share (28,800 underlying)
    28,800
Footnotes (12)
  • [F1]Includes (i) 94,496 shares of our common stock held jointly by Dr. Gelbfish and his wife, and (ii) 70,872 shares of our common stock held by Dr. Gelbfish as custodian for certain of his children.
  • [F10]These warrants became exercisable upon the consummation of the Company's initial public offering.
  • [F11]Includes 8% Noteholder Warrants held by Dr. Gelbfish and his wife jointly, that are exercisable for 38,400 shares of common stock, and 8% Noteholder Warrants held by Dr. Gelbfish as custodian for certain of his children that are exercisable for 28,800 shares of common stock.
  • [F12]Does not represent a sale in the market; represents the cashless exercise through the forfeiture of shares to the Issuer to pay the purchase price of the shares acquired upon conversion of the warrant.
  • [F2]Held by Landmark Foundation, of which Dr. Gelbfish and his wife are trustees.
  • [F3]The options vested 100% on January 10, 2014.
  • [F4]The options vest in full on the first anniversary of the date of grant.
  • [F5]On January 8, 2014, the reporting person acquired in a private placement (i) 50,000 shares of the Company's Series C-3 Non-Voting Convertible Preferred Stock, each share is convertible into 10 shares of Common Stock, $0.001 par value per share at a conversion price of $1.00 per share; and (ii) a five-year warrant to purchase common stock at an exercise price of $1.25 per share. The Series C-3 Preferred Stock and the warrants were purchased together at a price of $10.00 per share for each share of Series C-3 Preferred Stock. The reporting person erroneously reported that 30,000 shares were acquired by him directly and 20,000 shares were acquired by his IRA; all were acquired directly by the reporting person.
  • [F6]These options vest quarterly over two years beginning June 30, 2013.
  • [F7]These options vest as follows: (a) fifty percent (50%) on the date of the issuance of the CE Mark certification for Neutrolin in Europe, which occurred on July 5, 2013, and (50%) on December 31, 2013.
  • [F8]These options vested on January 14, 2012.
  • [F9]These options vest as follows: 1/3 on March 30, 2010, an additional 1/3 on March 30, 2011, and the remaining 1/3 on March 30, 2012.

Documents

1 file

Issuer

CorMedix Inc.

CIK 0001410098

→
Entity typeoperating
IncorporatedDE

Related Parties

1
  • filerCIK 0001410098

Filing Metadata

Form type
4
Filed
Jan 21, 7:00 PM ET
Accepted
Jan 22, 4:09 PM ET
Size
25.7 KB
View on SEC.gov